文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-DOTA-NT-20.3 神经降压素受体1 PET 显像作为前列腺癌神经内分泌分化的替代标志

68Ga-DOTA-NT-20.3 Neurotensin Receptor 1 PET Imaging as a Surrogate for Neuroendocrine Differentiation of Prostate Cancer.
PubMed 文献 · J Nucl Med · 2022-02-17

本研究合成神经降压素受体1(NTR1)靶向示踪剂68Ga-DOTA-NT-20.3,并在雄激素依赖(LNCap)与雄激素非依赖(PC3)移植瘤中评估其亲和力与体内分布。PC3移植瘤1小时摄取高(4.95±0.67 %ID/g),经神经降压素特异性阻断后降至1.95±0.17 %ID/g(P<0.01,t=8.72),而LNCap移植瘤摄取低,与68Ga-PSMA-11分布相反。作者认为该示踪剂制备高效、分布良好、NTR1亲和力强,有望用于检测PSMA阴性前列腺癌并识别神经内分泌分化。

要点

  • 68Ga-DOTA-NT-20.3标记产率88.07%±1.26%,放射化学纯度至少99%,稳定性良好。
  • PC3移植瘤1小时摄取4.95±0.67 %ID/g,特异性阻断后降至1.95±0.17 %ID/g(P<0.01,t=8.72)。
  • LNCap移植瘤1小时摄取0.81±0.06 %ID/g,68Ga-PSMA-11在LNCap为8.60±2.11 %ID/g、PC3为0.53±0.05 %ID/g。

核心结论

  • 68Ga-DOTA-NT-20.3可高效制备,产率高、放射化学纯度高。
  • 其良好的体内分布与突出的NTR1亲和力使68Ga-DOTA-NT-20.3成为检测PSMA阴性前列腺癌并识别神经内分泌分化的潜在放射性药物。

研究设计与样本

  • 本研究合成NTR1靶向示踪剂68Ga-DOTA-NT-20.3,并测定其对雄激素依赖(LNCap)与雄激素非依赖(PC3)移植瘤的亲和力。
  • 采用自动化合成模块标记68Ga-DOTA-NT-20.3,用放射高效液相色谱分析其稳定性、标记产率与放射化学纯度。
  • 在NTR1阳性PC3细胞中通过竞争结合实验评估受体结合亲和力。
  • 通过小动物PET显像评估68Ga-DOTA-NT-20.3在PC3与LNCap移植瘤体内的生物分布。
  • 通过免疫组织化学与免疫荧光评估NTR1表达。

主要发现

  • 68Ga-DOTA-NT-20.3合成成功,产率88.07%±1.26%,放射化学纯度至少99%,稳定性良好。
  • 68Ga-DOTA-NT-20.3对NTR1的亲和力(半数抑制浓度)为7.59±0.41 nM。
  • PC3移植瘤小动物PET/CT显示高对比图像与强烈肿瘤摄取,提示特异性NTR1表达;1小时肿瘤放射性为4.95±0.67 %ID/g,经神经降压素特异性阻断后降至1.95±0.17 %ID/g(P<0.01,t=8.72)。
  • LNCap移植瘤1小时对68Ga-DOTA-NT-20.3无明显蓄积(0.81±0.06 %ID/g);68Ga-PSMA-11主要浓聚于LNCap移植瘤(8.60±2.11 %ID/g),PC3肿瘤无明显摄取(0.53±0.05 %ID/g),与体外免疫组织化学结果一致。
  • 生物分布评估显示血液与主要器官(脑、心、肺、肝、肌肉、骨)快速清除,注射后60分钟肿瘤/肝比值4.41±0.73、肿瘤/肌肉比值12.34±1.32。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostate-specific membrane antigen (PSMA)-negative neuroendocrine prostate cancer (PCa) is a subtype of PCa likely to be lethal, with limited clinical diagnostic and therapeutic options. High expression of neurotensin receptor subtype 1 (NTR1) is associated with neuroendocrine differentiation of PCa, which makes NTR1 a potential target for neuroendocrine PCa. In this study, the NTR1-targeted tracer 68Ga-DOTA-NT-20.3 was synthesized, and its affinity to androgen-dependent (LNCap) and androgen-independent (PC3) xenografts was determined. Methods: 68Ga-DOTA-NT-20.3 was labeled using an automated synthesizer module, and its stability, labeling yield, and radiochemical purity were analyzed by radio-high-performance liquid chromatography. Receptor binding affinity was evaluated in NTR1-positive PC3 cells by a competitive binding assay. The biodistribution of 68Ga-DOTA-NT-20.3 in vivo was evaluated in PC3 and LNCap xenografts by small-animal PET imaging. NTR1 expression was identified by immunohistochemistry and immunofluorescence evaluation. Results: 68Ga-DOTA-NT-20.3 was synthesized successfully, with a yield of 88.07% ± 1.26%, radiochemical purity of at least 99%, and favorable stability. The NTR1 affinity (half-maximal inhibitory concentration) for 68Ga-DOTA-NT-20.3 was 7.59 ± 0.41 nM. Small-animal PET/CT of PC3 xenograft animals showed high-contrast images with intense tumor uptake, which revealed specific NTR1 expression. The tumors showed significant radioactivity (4.95 ± 0.67 percentage injected dose per gram of tissue [%ID/g]) at 1 h, which fell to 1.95 ± 0.17 %ID/g (P < 0.01, t = 8.72) after specific blockage by neurotensin. LNCap xenografts had no significant accumulation (0.81 ± 0.06 %ID/g) of 68Ga-DOTA-NT-20.3 at 1 h. In contrast, 68Ga-PSMA-11 was concentrated mainly in LNCap xenografts (8.60 ± 2.11 %ID/g), with no significant uptake in PC3 tumors (0.53 ± 0.05 %ID/g), consistent with the in vitro immunohistochemistry findings. Biodistribution evaluation showed rapid clearance from the blood and main organs (brain, heart, lung, liver, muscle, and bone), with significantly high tumor-to-liver (4.41 ± 0.73) and tumor-to-muscle (12.34 ± 1.32) ratios at 60 min after injection. Conclusion: 68Ga-DOTA-NT-20.3 can be efficiently prepared with a high yield and high radiochemical purity. Its favorable biodistribution and prominent NTR1 affinity make 68Ga-DOTA-NT-20.3 a potential radiopharmaceutical for the detection of PSMA-negative PCa and identification of neuroendocrine differentiation.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Wu W, Yu F, Zhang P, et al. 68Ga-DOTA-NT-20.3 Neurotensin Receptor 1 PET Imaging as a Surrogate for Neuroendocrine Differentiation of Prostate Cancer. J Nucl Med. 2022. PMID: 35177423. doi:10.2967/jnumed.121.263132

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。